Back
12 - 15 February

TANDEM 2025 ASCT & CIBMTR

HONOLULU

Kite at Tandem 2025

At TANDEM 2025, we are excited to share new
data across different therapies and indications,
solidifying our goal to bring the promise of cell
therapy to as many eligible patients as possible.
Learn more about the cell therapy sponsored and
supported/collaborative studies below

Time to CAR T Infusion in Local Versus Distant Treatment Centers
405

Intersectionality, Diversity, and Inclusion & Removing Barriers to Access

Anik Patel et al
Hawai'i Convention Center, Honolulu
Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care (SOC) in Patients With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)
244

Engineered Immune Cells (CAR-T, NK, TCR): Clinical Immune Effector Cells for Heme Malignancies

Jason Westin et al
Hawai'i Convention Center, Honolulu
Incidence of Cytokine Release Syndrome and Neurological Events in Patients With Relapsed or Refractory Large B-cell Lymphoma at and Beyond 2 Weeks Following Axicabtagene Ciloleucel Infusion
272

Engineered Immune Cells (CAR-T, NK, TCR): Clinical - Immune Effector Cells for Heme Malignancies

Marie Jose Kersten et al
Hawai'i Convention Center, Honolulu
Real World Treatment Patterns of Large B-Cell Lymphoma Patients Over Time in a Post-CAR T Approval Era
469

Lymphoma/CLL — Clinical

Miguel-Angel Perales et al
Hawai'i Convention Center, Honolulu
A United States (US) Cost-Effectiveness Analysis of Axicabtagene Ciloleucel Vs Odronextamab in Third Line or Later (3L+)Treatment of Diffuse Large B-Cell Lymphoma
562
Frederick Locke et al
Hawai'i Convention Center, Honolulu
Short-Term Costs Associated with Outpatient Use of Axicabtagene Ciloleucel in Second-Line Relapsed/Refractory Large B-Cell Lymphoma Based on ZUMA-24 Clinical Trial
563
Olalekan Oluwole et al
Hawai'i Convention Center, Honolulu
Lymphoma/CLL — Clinica
60

Engineered Immune Cells (CAR-T, NK, TCR): Clinical - Immune Effector Cells for Heme Malignancies

Soumya Poddar
Hawai'i Convention Center, Honolulu

Rapid Increase in Blood CD19 CAR-T Vector Load During the First 5 Days Post Infusion is Associated with Severe ICANS
279

Engineered Immune Cells: Clinical — Immune Effector Cells for Heme Malignancies

Anik Patel et al
Hawai'i Convention Center, Honolulu